RNA - Avidity Biosciences Inc Stock Price, Fair Value and News

$43.65+0.40 (+0.92%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

RNA Price Action

Last 7 days

-16.9%

Last 30 days

-6.5%

Last 90 days

1.9%

Trailing 12 Months

644.9%

RNA RSI Chart

RNA Valuation

Market Cap

5.2B

Price/Earnings (Trailing)

-18.57

Price/Sales (Trailing)

212.31

Price/Free Cashflow

-27.63

RNA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

RNA Fundamentals

RNA Revenue

Revenue (TTM)

24.5M

Rev. Growth (Yr)

-17.1%

Rev. Growth (Qtr)

14.23%

RNA Earnings

Earnings (TTM)

-280.5M

Earnings Growth (Yr)

-53.55%

Earnings Growth (Qtr)

-13.57%

RNA Profitability

Return on Equity

-18.66%

Return on Assets

-17.09%

Free Cashflow Yield

-3.62%

RNA Investor Care

Shares Dilution (1Y)

61.01%

Diluted EPS (TTM)

-2.89

RNA Alerts

3 major insider sales recently.

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	25.3M	25.0M	24.5M	0
2023	5.4M	7.1M	7.5M	24.0M
2022	7.8M	6.8M	5.9M	5.0M
2021	8.1M	9.2M	9.6M	8.7M
2020	3.7M	5.0M	6.1M	6.8M
2019	0	1.0M	1.7M	2.3M
2018	0	0	0	379.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Avidity Biosciences Inc

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease is under phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of Duchenne Muscular Dystrophy, which is under phase 1/2 clinical trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy is in phase 1/2 clinical trial. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

CEO	Ms. Sarah Boyce
WEBSITE	aviditybiosciences.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	186

Avidity Biosciences Inc Frequently Asked Questions

What is the ticker symbol for Avidity Biosciences Inc? What does RNA stand for in stocks?

RNA is the stock ticker symbol of Avidity Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Avidity Biosciences Inc (RNA)?

As of Wed Nov 20 2024, market cap of Avidity Biosciences Inc is 5.21 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RNA stock?

You can check RNA's fair value in chart for subscribers.

Is Avidity Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether RNA is over valued or under valued. Whether Avidity Biosciences Inc is cheap or expensive depends on the assumptions which impact Avidity Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RNA.

What is Avidity Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Nov 20 2024, RNA's PE ratio (Price to Earnings) is -18.57 and Price to Sales (PS) ratio is 212.31. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RNA PE ratio will change depending on the future growth rate expectations of investors.